Finance

Lists
PAHC:NASDAQ
Phibro Animal Health Corp
$37.51
-1.93%
(-0.74) 1D
Sep 8, 12:30:25 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PAHC...
Open
$37.92
High
$37.92
Low
$36.86
Mkt. cap
1.52B
Avg. vol.
222.80K
Volume
43.14K
Dividend
1.28%
Quarterly dividend
$0.12
Ex-dividend date
Sep 2, 2026
P/E ratio
15.41
52-wk high
$60.08
52-wk low
$28.25
EPS
$2.43
Beta
0.47
Shares outstanding
21.11M
No. of employees
3K
Open
$37.92
High
$37.92
Low
$36.86
Mkt. cap
1.52B
Avg. vol.
222.80K
Volume
43.14K
Dividend
1.28%
Quarterly dividend
$0.12
Ex-dividend date
Sep 2, 2026
P/E ratio
15.41
52-wk high
$60.08
52-wk low
$28.25
EPS
$2.43
Beta
0.47
Shares outstanding
21.11M
No. of employees
3K
Profile
Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated in Delaware. Wikipedia
About Phibro Animal Health Corp
CEO-
Employees2.6K
Founded1946
HeadquartersTeaneck, New Jersey, United States
SectorPharmaceutical industry
Websitepahc.com
Analyst ratings
Based on 2 analysts giving stock ratings to PAHC in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PAHC in the last 3 months.
Highest
Current $37.51
$55.00 (+46.63%)
Average
$45.00 (+19.97%)
Lowest
$35.00 (-6.69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ekaterina Knyazkova
J.P. Morgan
Buy
Maintained
$55.00
+46.6%
09/01/2026
Michael Ryskin
Bank of America Securities
Sell
Reiterated
$35.00
-6.7%
08/27/2026
Daniel Grosslight
Citi
Hold
Reiterated
$44.00
+17.3%
05/14/2026
Erin Wright
Morgan Stanley
Hold
Maintained
$49.00
+30.6%
02/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
363.89M
373.91M
383.54M
396.75M
Cost of goods sold
242.99M
240.42M
257.87M
270.85M
Cost of revenue
242.99M
240.42M
257.87M
270.85M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
72.05M
78.50M
77.50M
81.27M
Operating expense
72.05M
78.50M
77.50M
83.68M
Total operating expenses
315.04M
318.92M
335.37M
354.52M
Operating income
48.85M
54.99M
48.17M
42.22M
Other non operating income
-
-
-
-
EBT including unusual items
36.27M
36.42M
32.31M
32.34M
EBT excluding unusual items
33.86M
41.09M
35.83M
26.41M
Income tax expense
9.74M
8.97M
8.29M
10.63M
Effective tax rate
26.86%
24.61%
25.65%
32.87%
Other operating expenses
-
-
-
-
Net income
26.53M
27.46M
24.02M
21.71M
Net profit margin
7.29%
7.34%
6.26%
5.47%
Earnings per share
0.73
0.87
0.76
0.85
Interest and investment income
484.00K
725.00K
250.00K
528.00K
Interest expense
-12.54M
-12.48M
-10.68M
-10.71M
Net interest expenses
-12.06M
-11.76M
-10.43M
-10.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
61.68M
67.88M
60.62M
54.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps